{"id":791180,"date":"2024-11-27T16:09:45","date_gmt":"2024-11-27T21:09:45","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/sensei-biotherapeutics-to-participate-in-citis-2024-global-healthcare-conference\/"},"modified":"2024-11-27T16:09:45","modified_gmt":"2024-11-27T21:09:45","slug":"sensei-biotherapeutics-to-participate-in-citis-2024-global-healthcare-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/sensei-biotherapeutics-to-participate-in-citis-2024-global-healthcare-conference\/","title":{"rendered":"Sensei Biotherapeutics to Participate in Citi\u2019s 2024 Global Healthcare Conference"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">BOSTON, Nov.  27, 2024  (GLOBE NEWSWIRE) &#8212; Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced that Company management will participate in Citi\u2019s 2024 Global Healthcare Conference, being held on December 3-5, in Miami, FL.<\/p>\n<p>\n        <strong>About Sensei Biotherapeutics\u00a0<\/strong>\u00a0<br \/>Sensei Biotherapeutics (Nasdaq: SNSE) is a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients. Through its TMAb\u2122 (Tumor Microenvironment Activated biologics) platform, Sensei develops conditionally active therapeutics designed to disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment to unleash T cells against tumors. Sensei\u2019s lead product candidate is SNS-101, a conditionally active antibody designed to block the V-domain Ig suppressor of T cell activation (VISTA) checkpoint selectively within the low pH tumor microenvironment, where VISTA acts as a suppressor of T cells by binding the receptor PSGL-1. For more information, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=gdMeZXS0R8bYXnB1fCYgntJnTBqkf25xyRxLd4htbTQtGvps9vVsdhFRD3fD0HtTNqbMC1ax0I3BWRzregmmi4OOMtwYelvyIcljASTLsXckTnZVU4FEgAyhYtMzwbIMo89m7DSuyxbXuyZOyLj7tBp1meAACaWhPe16Gvl88zb958R4BAmzCaP-97I7P2TPTd7BbxEBUgTrTGEl2UbS_uW2eCNMZS63pvYTWHwhD6VwgFm4SRASTCIYarDxKeiyzrw4fok8vHYH48xJP3Dhd-RzinglfLXxiFUCAWrqv8dJzDO58xsQe9LNts51k4XD09Bnu7MHU19UOXyJw77jMlXj_G58_c05X86NpdBa7pszwj8PWkxfoMQtP-HiTt27ZVUIwmTDTMYVCQIwGvSuIjlu_fhuXMup3pba3UCB8N4=\" rel=\"nofollow\" target=\"_blank\">www.senseibio.com<\/a>, and follow the company on X @SenseiBio and <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=hMerV9rEHhJrW67hu4xKFHFcSIWjxqgVNfUzFeDPMEtDBBEWXLRmMUU-cdtpewoizt_uFZ4-sRO-0Wm2Vbhi-NZbCVURXuREQzUNqL2h-f9jQKJ6rZ6LCZlBDzZNgY7SVKtQqFmPIidW3yR_InYTNvZ3q0_8nGx46xIZHNAjGM6WYcVir-jKUzI_ho5TdZ7bHKH5PxRrjWXPEhuY6PBPXirEvcyhc4Lg73ZDE9OWIAzFqrxUNxR6r1REGi0Nyp6Qqo1ToWgFs7L4pJYweQPPP2byvRtW335GR8AG9qM-7ALzHPTZCTMvPFjdg7T84FNteGrXawAuhzFxZqe24ZfC3OfBApCFfjZQbjaFehm2cXFoY2tUGrFLOuJIOQUOVa2tS6t_62AYTJDBoH0TN2yAAjKEkFLcNX8vOxiqCFNNZJXsI0obQBzGurygKlStPWwR\" rel=\"nofollow\" target=\"_blank\">LinkedIn<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>Investor Contact:<\/strong><br \/>\n        <br \/>Michael Biega<br \/>Senior Director, Investor Relations<br \/>Sensei Biotherapeutics<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=SA0ErtGc4KxzZ8a_wbFLi6XWWOa_I7LDsbHsoX9shsMrnqkoV9o2_mCX7Bbk2GWSV2m-GMAvEgCBQ3o86vSyaSCkUaNEPfjArz5qDfs6874=\" rel=\"nofollow\" target=\"_blank\">mbiega@senseibio.com<\/a><\/p>\n<p align=\"justify\">\n        <strong>Media Contact:<\/strong><br \/>\n        <br \/>Joyce Allaire<br \/>LifeSci Advisors<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=tSeoF6Dg5mhbIscYLSBaLhPyG1IBaskHwPvCwTgQFjrRKd4czBFzvqlnNR_hL5OR43DLSWYk92aCzG5s7j7xPHMTQ8cRVvSjqK6ufnb8De_9-ZAMSj8xa8nMzIpEBlBW\" rel=\"nofollow\" target=\"_blank\">Jallaire@lifesciadvisors.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTI5MTA3NCM2NjEzOTY0IzIyMDQ0Nzc=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/ZTExZDljZDctNWM1My00ZDQ5LWFiMDYtZWVmYjBlZTQ5YzI1LTEyMTYwMzA=\/tiny\/Sensei-Biotherapeutics.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>BOSTON, Nov. 27, 2024 (GLOBE NEWSWIRE) &#8212; Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced that Company management will participate in Citi\u2019s 2024 Global Healthcare Conference, being held on December 3-5, in Miami, FL. About Sensei Biotherapeutics\u00a0\u00a0Sensei Biotherapeutics (Nasdaq: SNSE) is a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients. Through its TMAb\u2122 (Tumor Microenvironment Activated biologics) platform, Sensei develops conditionally active therapeutics designed to disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment to unleash T cells against tumors. Sensei\u2019s lead product candidate is SNS-101, a conditionally active antibody designed to block &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/sensei-biotherapeutics-to-participate-in-citis-2024-global-healthcare-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Sensei Biotherapeutics to Participate in Citi\u2019s 2024 Global Healthcare Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-791180","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Sensei Biotherapeutics to Participate in Citi\u2019s 2024 Global Healthcare Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/sensei-biotherapeutics-to-participate-in-citis-2024-global-healthcare-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sensei Biotherapeutics to Participate in Citi\u2019s 2024 Global Healthcare Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"BOSTON, Nov. 27, 2024 (GLOBE NEWSWIRE) &#8212; Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced that Company management will participate in Citi\u2019s 2024 Global Healthcare Conference, being held on December 3-5, in Miami, FL. About Sensei Biotherapeutics\u00a0\u00a0Sensei Biotherapeutics (Nasdaq: SNSE) is a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients. Through its TMAb\u2122 (Tumor Microenvironment Activated biologics) platform, Sensei develops conditionally active therapeutics designed to disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment to unleash T cells against tumors. Sensei\u2019s lead product candidate is SNS-101, a conditionally active antibody designed to block &hellip; Continue reading &quot;Sensei Biotherapeutics to Participate in Citi\u2019s 2024 Global Healthcare Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/sensei-biotherapeutics-to-participate-in-citis-2024-global-healthcare-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2024-11-27T21:09:45+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTI5MTA3NCM2NjEzOTY0IzIyMDQ0Nzc=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sensei-biotherapeutics-to-participate-in-citis-2024-global-healthcare-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sensei-biotherapeutics-to-participate-in-citis-2024-global-healthcare-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Sensei Biotherapeutics to Participate in Citi\u2019s 2024 Global Healthcare Conference\",\"datePublished\":\"2024-11-27T21:09:45+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sensei-biotherapeutics-to-participate-in-citis-2024-global-healthcare-conference\\\/\"},\"wordCount\":197,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sensei-biotherapeutics-to-participate-in-citis-2024-global-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTI5MTA3NCM2NjEzOTY0IzIyMDQ0Nzc=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sensei-biotherapeutics-to-participate-in-citis-2024-global-healthcare-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sensei-biotherapeutics-to-participate-in-citis-2024-global-healthcare-conference\\\/\",\"name\":\"Sensei Biotherapeutics to Participate in Citi\u2019s 2024 Global Healthcare Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sensei-biotherapeutics-to-participate-in-citis-2024-global-healthcare-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sensei-biotherapeutics-to-participate-in-citis-2024-global-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTI5MTA3NCM2NjEzOTY0IzIyMDQ0Nzc=\",\"datePublished\":\"2024-11-27T21:09:45+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sensei-biotherapeutics-to-participate-in-citis-2024-global-healthcare-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sensei-biotherapeutics-to-participate-in-citis-2024-global-healthcare-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sensei-biotherapeutics-to-participate-in-citis-2024-global-healthcare-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTI5MTA3NCM2NjEzOTY0IzIyMDQ0Nzc=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTI5MTA3NCM2NjEzOTY0IzIyMDQ0Nzc=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sensei-biotherapeutics-to-participate-in-citis-2024-global-healthcare-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Sensei Biotherapeutics to Participate in Citi\u2019s 2024 Global Healthcare Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Sensei Biotherapeutics to Participate in Citi\u2019s 2024 Global Healthcare Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/sensei-biotherapeutics-to-participate-in-citis-2024-global-healthcare-conference\/","og_locale":"en_US","og_type":"article","og_title":"Sensei Biotherapeutics to Participate in Citi\u2019s 2024 Global Healthcare Conference - Market Newsdesk","og_description":"BOSTON, Nov. 27, 2024 (GLOBE NEWSWIRE) &#8212; Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced that Company management will participate in Citi\u2019s 2024 Global Healthcare Conference, being held on December 3-5, in Miami, FL. About Sensei Biotherapeutics\u00a0\u00a0Sensei Biotherapeutics (Nasdaq: SNSE) is a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients. Through its TMAb\u2122 (Tumor Microenvironment Activated biologics) platform, Sensei develops conditionally active therapeutics designed to disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment to unleash T cells against tumors. Sensei\u2019s lead product candidate is SNS-101, a conditionally active antibody designed to block &hellip; Continue reading \"Sensei Biotherapeutics to Participate in Citi\u2019s 2024 Global Healthcare Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/sensei-biotherapeutics-to-participate-in-citis-2024-global-healthcare-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2024-11-27T21:09:45+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTI5MTA3NCM2NjEzOTY0IzIyMDQ0Nzc=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sensei-biotherapeutics-to-participate-in-citis-2024-global-healthcare-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sensei-biotherapeutics-to-participate-in-citis-2024-global-healthcare-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Sensei Biotherapeutics to Participate in Citi\u2019s 2024 Global Healthcare Conference","datePublished":"2024-11-27T21:09:45+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sensei-biotherapeutics-to-participate-in-citis-2024-global-healthcare-conference\/"},"wordCount":197,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sensei-biotherapeutics-to-participate-in-citis-2024-global-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTI5MTA3NCM2NjEzOTY0IzIyMDQ0Nzc=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sensei-biotherapeutics-to-participate-in-citis-2024-global-healthcare-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/sensei-biotherapeutics-to-participate-in-citis-2024-global-healthcare-conference\/","name":"Sensei Biotherapeutics to Participate in Citi\u2019s 2024 Global Healthcare Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sensei-biotherapeutics-to-participate-in-citis-2024-global-healthcare-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sensei-biotherapeutics-to-participate-in-citis-2024-global-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTI5MTA3NCM2NjEzOTY0IzIyMDQ0Nzc=","datePublished":"2024-11-27T21:09:45+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sensei-biotherapeutics-to-participate-in-citis-2024-global-healthcare-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/sensei-biotherapeutics-to-participate-in-citis-2024-global-healthcare-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sensei-biotherapeutics-to-participate-in-citis-2024-global-healthcare-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTI5MTA3NCM2NjEzOTY0IzIyMDQ0Nzc=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTI5MTA3NCM2NjEzOTY0IzIyMDQ0Nzc="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sensei-biotherapeutics-to-participate-in-citis-2024-global-healthcare-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Sensei Biotherapeutics to Participate in Citi\u2019s 2024 Global Healthcare Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/791180","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=791180"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/791180\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=791180"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=791180"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=791180"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}